NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

PROCEPT BioRobotics Corporation (PRCT) Stock Analysis

PROCEPT BioRobotics Corporation (PRCT) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

PRCT

$22.76

+$1.39 (+6.50%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PRCT with… →

PRCT Key Statistics

As of Sep 4, 2026
Trading
Open
$21.19
Previous Close
$21.37
Day's Range
20.89–22.84
52-Week Range
16.67–41.51
Volume
1.27M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.90
Valuation
Market Cap
$1.30B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.84
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.95
Financials (FY)
Revenue (FY)
$308.05M+37.22%
Net Income (FY)
−$95.57M
Profit marginThe share of revenue left as profit after all costs and taxes.
−32.53%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
56.92M
1-Year Return
−40.64%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
1.60M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PRCT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−27.65%
2025−60.93%
2024+92.13%
2023+0.89%
2022+66.09%
2021 (partial year)−40.37%

As of September 4, 2026.

PRCT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$308.05M−$95.57M−31.0%
2024$224.50M−$91.41M−40.7%
2023$136.19M−$105.90M−77.8%
2022$75.01M−$87.15M−116.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$308.05M$196.23M−$103.86M−$95.57M−31.0%
2024$224.50M$137.10M−$96.61M−$91.41M−40.7%
2023$136.19M$71.05M−$109.17M−$105.90M−77.8%
2022$75.01M$37.09M−$80.72M−$87.15M−116.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PRCT Valuation vs Medical Devices Median

Median of 151 stocks
MetricPRCTMedical Devices medianvs median
P/S ratio3.842.9829% above
Profit margin−32.53%−1.69%30.8 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

PROCEPT BioRobotics Corporation (PRCT) is capitalised at $1.30B on the latest close. The company sits in the Healthcare sector, in the Medical Devices industry. The company reports 888 employees.

PRCT last closed at $22.76 on September 4, 2026. That is +$1.39 (+6.50%) against the previous close. The 52-week range on file runs from $16.67 to $41.51. The latest close sits 36.57% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $308.05M. That is +37.22% against the prior fiscal year, when revenue was $224.50M. The same year closed with a net loss of $95.57M. Profit margin runs at −32.54%. That is 30.8 percentage points below the Medical Devices median of −1.69%. Trailing earnings per share are −1.95.

Across the 4 fiscal years on file, revenue moves from $75.01M in 2022 to $308.05M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 3.84. On price-to-sales that is 29.04% above the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

The reported beta is 0.9. Daily returns over the trailing 5 years annualize to a volatility of 64.79%. Over the trailing twelve months the price has returned −40.64%. Across 5 years the annualized return works out at −11.51%.

Growth & Income

No dividend is on file for PRCT.

So far in 2026 the price is −27.65%. Across the complete calendar years on file, 2024 returned +92.13% and 2025 returned −60.93%. Of the 4 complete calendar years on file, 3 finished higher.

Peer Comparison

PROCEPT BioRobotics Corporation (PRCT) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
PROCEPT BioRobotics Corporation PRCT $1.30B —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. PROCEPT BioRobotics Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Visit website →